Heart procedure to close an atrial clot risk pouch in kidney failure
Part of Heart & circulation, Kidney & urinary clinical trials.
This trial tests a heart procedure that closes a part of the heart called the left atrial appendage to help prevent stroke in people with an irregular heartbeat (atrial fibrillation) and very advanced kidney disease. It’s mainly for patients who can take the needed blood-thinner medicines and who do not already have a clot in that pouch.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- A doctor has diagnosed atrial fibrillation that is not related to heart valve disease
- Your stroke risk is high enough (CHA2DS2-VASc score 2 or more)
- Your kidney function is very low (KDOQI stage 5, eGFR under 15), with or without dialysis
- You can legally and safely take aspirin and/or clopidogrel (no absolute allergy/contraindication)
- There is no clot inside the left atrial appendage found on screening tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a minimally invasive procedure to close off a part of the heart (the left atrial appendage) in people with kidney failure on dialysis who also have atrial fibrillation. The goal is to reduce the risk of stroke without needing long-term blood thinners.
This trial tests the Zenith system, a device that seals off a heart area called the left atrial appendage to reduce stroke risk in people with atrial fibrillation (AF). You may be eligible if you have AF and a doctor recommends LAA closure, and you can return for follow-up scans and visits.
This trial compares a minimally invasive keyhole surgery to close the left atrial appendage (a small pocket in the heart where clots can form) with continuing blood-thinning medication. It aims to lower stroke risk for people with atrial fibrillation who have a high risk of bleeding or cannot take blood thinners.
This trial looks at the best blood-thinning (antiplatelet) plan after a left atrial appendage closure procedure in people with kidney failure on dialysis. It may help reduce stroke risk while also lowering medicine-related side effects.
This study tests whether closing a heart pocket called the left atrial appendage can lower future stroke or other clot-related events in people with atrial fibrillation. It’s mainly for people who have had a prior clot-related event or are at higher risk but may not be good candidates for long-term blood thinners.
This trial tests a procedure that closes off a small pouch in the heart (left atrial appendage) while also treating irregular heartbeat (atrial fibrillation) with a catheter ablation procedure. The goal is to reduce your stroke risk and treat your symptoms without needing blood thinners long-term.
Hear when a new Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.